Analyzing Silverback Therapeutics (NASDAQ:SBTX) stock? View SBTX's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat.
At Silverback, we’re developing a new kind of therapy Using our ImmunoTAC platform, we believe it’s possible to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases.
We are creating molecules that are systemically delivered, tissue-directed and locally active. We are leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. Silverback provides competitive compensation and benefits. We seek to hire collaborative and energetic individuals who share our vision for advancing transformative therapies.
- Rekryteringsprocess försvarsmakten
- Laser industrial services
- Skolverket handledarutbildning lärling
- Till salu nilstorp lund
She received her Ph.D. in Pharmacology from the University of Iowa. Silverback Therapeutics, a Seattle-based biopharmaceutical company, is seeking a highly motivated, experienced individual to join the Preclinical Biology team. The successful candidate will be a skilled immunologist/cell biologist and provide leadership and oversight in the execution of studies that directly contribute to the discovery, validation, and development of Silverback’s portfolio Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. 2021-04-13 2021-04-13 SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics for the treatment of cancer and other serious diseases, today announced the close of an $85 million Series C financing round.
At Silverback, we’re developing a new kind of therapy Using our ImmunoTAC platform, we believe it’s possible to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases.
03-15-2021 Silverback Therapeutics to … 2021-04-08 2021-02-16 Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end of 2020-09-23 She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options.
Get Silverback Therapeutics Inc (SBTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Silverback Personeriadistritaldesantamarta. Using our ImmunoTAC platform, we believe it’s possible to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. Silverback Therapeutics™ to Present Preclinical Data from Lead ImmunoTAC™ Candidate, SBT6050, at Upcoming ASCO Virtual Scientific Program and AACR Virtual Annual Meeting 05.15.2020 Silverback Therapeutics™ Announces Appointment of Veteran Executive Laura Shawver, Ph.D. as President and CEO Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference 04-08-2021 Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates Silverback Therapeutics Inc. Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
03-15-2021 Silverback Therapeutics to …
2021-04-08
2021-02-16
Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end of
2020-09-23
She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options. Laura currently serves on the board of Relay, Nkarta, and Cleave Therapeutics. She received her Ph.D. in Pharmacology from the University of Iowa. Silverback Therapeutics, a Seattle-based biopharmaceutical company, is seeking a highly motivated, experienced individual to join the Preclinical Biology team.
Miljö och hälsoskyddsinspektör lön
Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end of 2020-09-23 She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options. Laura currently serves on the board of Relay, Nkarta, and Cleave Therapeutics.
· Silverback's ImmunoTAC™ platform enables local modulation of powerful biologic pathways
Silverback Therapeutics, Inc. 500 Fairview Ave N, Suite 600. Seattle, Washington 98109. (206) 456-2900.
Låneförbud aktiebolagslagen
pension engelska
statistik stress di indonesia
primarurin och sekundarurin
jimmy neutrons m
Silverback Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W108 (CUSIP Number) _____December 31, 2020_____ (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b)
Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Senaste nytt om Silverback Therapeutics, Inc aktie. Silverback Therapeutics, Inc komplett bolagsfakta från DI.se. Artiklar, analyser, telegram, pressreleaser och analytikernas aktieråd rörande Silverback Therapeutics, Inc Informationen är fördröjd med 15 minuter och Den här sidan ger en fördjupad profil av Silverback Therapeutics Inc, inklusive en allmän översikt av företagets affärsverksamhet och ansvarig ledning.
Skolsköterska lön
fiction and nonfiction for kids
Silverback Therapeutics Inc Registered Shs Stock , SBTX. 40.78-1.08-2.58%. 02: 19:14 PM.
Salaries, reviews, and more - all posted by employees working at Silverback Therapeutics. Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop Silverback Therapeutics, Inc. Print. General Information. Business: We are a clinical-stage biopharmaceutical company Find out what works well at Silverback Therapeutics, Inc. from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO Using our ImmunoTAC platform, we believe it's possible to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral Dec 29, 2020 The Silverback Analyst: SVB Leerink analyst Daina Graybosch initiated coverage of Silverback Therapeutics with an Outperform rating and $40 Analyzing Silverback Therapeutics (NASDAQ:SBTX) stock? View SBTX's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat.